{"id":66350,"date":"2022-04-28T16:05:13","date_gmt":"2022-04-28T16:05:13","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=90898"},"modified":"2022-04-28T16:05:13","modified_gmt":"2022-04-28T16:05:13","slug":"informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report","status":"publish","type":"post","link":"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/","title":{"rendered":"Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report"},"content":{"rendered":"<h4 align=\"center\">New Report Highlights Key Industry Trends in Pharmaceutical R&amp;D<\/h4>\n<p align=\"left\">NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) &#8212;\u00a0<a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3Dw0sV-ozDh5_sYRdy_wTN73GrZx1z0_luxzCSbS36wRK0Wxg4BkkzENb-EbC4jvKtC7saXs-VfqJ87LYhcRF8qCHPlUAU7I8z1_6hIQLPvpcpFjrubblGPQBHRINGvbr8&amp;source=gmail-html&amp;ust=1651248284748000&amp;usg=AOvVaw2KAZKQqfp82nfz-0XnIa9E\"  rel=\"nofollow noreferrer\">Informa Pharma Intelligence<\/a>, the global business intelligence provider for the biopharma industry, and The American Society of Gene &amp; Cell Therapy (ASGCT), today announced the launch of the\u00a0<a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DwPZdVXT0t_VqHnL9mLY0O99oIpne2F3Fex9vb99TKIqpg5YIB3ydxVfz9jSE2bIGM-iB5VS_IIUjuZqbzIdZTE2esWI6VdeEgnDJTKLgAgsw1v3CwlAQ9_ljFn1vTzfytOeia1wsqDGR7OjIMhhfMestHgRzuFkJLzj-VaW4rfwAq5WTjPy2YEbrEGi51NPc&amp;source=gmail-html&amp;ust=1651248284748000&amp;usg=AOvVaw3vcf-X8CRqChEb_INc503-\"  rel=\"nofollow noreferrer\">Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report<\/a>. The Q1 2022 report assesses industry trends by examining approved gene, cell and RNA therapies, the pharmaceutical pipeline by company, most targeted therapeutic areas, and an overview of recent dealmaking and start-up funding.<\/p>\n<p>Notable findings from the first quarterly report of the year include:<\/p>\n<ul type=\"disc\">\n<li><strong>FDA Approvals\u00a0<\/strong><strong>\u2013\u00a0<\/strong>Since Q4 2021, one new genetically modified cell therapy has been approved and one new gene therapy has filed for approval. Carvykti, a CAR-T cell therapy developed by Legend Biotech and Johnson &amp; Johnson, was approved for multiple myeloma in the U.S. and EtranaDez (etranacogene dezaparvovec), an AAV5 gene therapy developed by uniQure, was filed for approval in the EU and UK for hemophilia B.<\/li>\n<li><strong>Gene Therapy Pipeline Growth\u00a0<\/strong><strong>\u2013<\/strong>\u00a0Since Q1 2021, the gene therapy pipeline has increased by 16% with 3,579 therapies in development, ranging from preclinical through preregistration. A total of 1,986 gene therapies (including genetically modified cell therapies such as CAR T-cell therapies) are in development, accounting for 55% of gene, cell and RNA therapies; and 816 non-genetically modified cell therapies are in development, accounting for 22% of gene, cell and RNA therapies.<\/li>\n<li><strong>Most Targeted Therapeutic Areas\u00a0<\/strong><strong>\u2013<\/strong>\u00a0Oncology and rare diseases continue to be the top areas of gene therapy development in both the overall pipeline (preclinical to preregistration) and in the clinic (Phase I to preregistration). Development for rare diseases most commonly occurs in the oncology space, representing a majority of 52% compared to non-oncology rare disease gene therapy pipeline development.<\/li>\n<li><strong>Deal Making\u00a0<\/strong>\u2013 A total of 123 deals were signed, a 15% decrease in volume from Q4 2021. Q1 2022 was the lowest quarter total within the last year, and acquisition and alliance volume quarter by quarter remained flat, while financings continue to trend down. Acquisitions were the only type of deal to increase in Q1 2022.<\/li>\n<li><strong>Start-up Financing\u00a0<\/strong>\u2013 Start-up financing by gene, cell and RNA therapeutic companies remained steady in Q1 2022. A total of 15 companies raised seed or Series A financing, totaling an aggregate $507.8M. The overall deal-making total across alliance, acquisitions and financings saw a 15% decline. In the largest start-up financing, Cellino Biotech, a Harvard University spin-out, raised $80M to support its large-scale production of autologous and allogeneic cell therapies.<\/li>\n<\/ul>\n<p>\u201cSince we started putting these quarterly reports together in Q1 2021, we have seen the gene therapy pipeline steadily increase. Oncology and rare disease remain the most targeted therapeutic areas, and we continue to see a strong pipeline for CAR-T cell therapies for cancer indications,\u201d said Ly Nguyen-Jatkoe, PhD, Executive Director, Americas, Informa Pharma Intelligence. \u201cRare diseases continue to be a focus for RNA therapies.\u201d<\/p>\n<p>\u201cThe continued approvals of gene and cell therapies has turned into one of the brightest spots in releasing this report each quarter,\u201d said David Barrett, JD, CEO, the American Society of Gene &amp; Cell Therapy (ASGCT). \u201cWith the approval of Carvykti in Q1 2022 and the ever-expanding pipeline, we\u2019re exceptionally optimistic about the future of the field.\u201d<\/p>\n<p>All pipeline and trial insights were compiled using data from Pharma Intelligence\u2019s Pharmaprojects\u2122, and Trialtrove\u2122, part of Citeline, which has been tracking global drug development since 1980. Deal, financing and catalyst data were derived from Biomedtracker\u2122. For more information, or to view the current and past reports, visit\u00a0<a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3Dw0sV-ozDh5_sYRdy_wTN73GrZx1z0_luxzCSbS36wRKauUneQQ7rXyxZySOSarVTVYW_8WfNaWxcA03oNrQEtIsoqdDVQKNe8pnA-WEAAfMvzo54ciBRdLEV_XK512bKRbXMT6VXq8dASKwKQ8GKiA%3D%3D&amp;source=gmail-html&amp;ust=1651248284749000&amp;usg=AOvVaw3g-KI222r0x8DUb4k9PeaX\"  rel=\"nofollow noreferrer\">Informa Pharma Intelligence<\/a>\u00a0or contact\u00a0<a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DUp9m-8abHyaMjdP3RHwHnksGQRL5Ao_CoReH3jNpfVmcX_9D-9sovStWFtdXOH59FDjlyeuoN-7TFDoTITaeeXLQpe1Misk9Dw9nxbVv7kU%3D&amp;source=gmail-html&amp;ust=1651248284749000&amp;usg=AOvVaw3VQhzkzVO-0fQlIo3db9nr\"  rel=\"nofollow noreferrer\">pharma@informa.com<\/a>.<\/p>\n<p><strong>About The American Society of Gene &amp; Cell Therapy (ASGCT)<\/strong><br \/>\nThe American Society of Gene &amp; Cell Therapy (ASGCT) is the primary professional membership organization for scientists, physicians, patient advocates and other professionals\u00a0with interest in gene and cell therapy.<\/p>\n<p>Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies.\u00a0ASGCT advances\u00a0knowledge, awareness and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.<\/p>\n<p><strong>About Informa Pharma Intelligence<\/strong><br \/>\nInforma Pharma Intelligence powers a full suite of analysis products \u2014 Datamonitor Healthcare\u2122, Sitetrove\u2122, Trialtrove\u2122, Pharmaprojects\u2122, Biomedtracker\u2122, Scrip\u2122, Pink Sheet\u2122 and In Vivo\u2122 \u2014 to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.<\/p>\n<p>With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&amp;D project isn\u2019t covered through the breadth and depth of data available to customers. For more information, visit\u00a0<a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DUp9m-8abHyaMjdP3RHwHnlLWHE67V9SwfmsGtMOzCL_ZucvXvo7YSBjJboK0WT33lNjsNk_HNpnzoPrF75lq04xjfZTxgCQvuvwPyKY5jfS9vkJg8eqsdP0ZCPlPupiN&amp;source=gmail-html&amp;ust=1651248284749000&amp;usg=AOvVaw2BTTFykuU7iPs2LA-4zxO5\"  rel=\"nofollow noreferrer\">pharmaintelligence.informa.com<\/a><\/p>\n<p><strong>Media Contacts:<\/strong><br \/>\nDiffusion PR for Informa Pharma Intelligence<br \/>\n<a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DDb6EoRZLh1GsQa4OhIkYQ_plYyG_AVwgUc5DYHaGgV_GjTLMbMBJGLifXdWzTSBc7X78sN_RuIxqfBErVWaxPmTCeRbHYM202Phl-gk-HrnDLBRWKhInJwwbaU0IpAO7&amp;source=gmail-html&amp;ust=1651248284749000&amp;usg=AOvVaw2-lv3CnWIKssjnztCNxoR9\"  rel=\"nofollow noreferrer\">informapharma@diffusionpr.com<\/a><\/p>\n<p>Alex Wendland for The American Society of Gene &amp; Cell Therapy (ASGCT)<br \/>\n<a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DL5CRH5suA14rsS6o6JOh8AMW3XMoqah2hCkGWV9A95kIUSC8yMgFHU_D_RdMjQjrGaaz2Psgn8kt7xMYhXHLsgu2Qf2ZxjT7m0U3nwZGsvc%3D&amp;source=gmail-html&amp;ust=1651248284749000&amp;usg=AOvVaw0qRLpASKHzUUZskg6xvn6P\"  rel=\"nofollow noreferrer\">AWendland@asgct.org<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Report Highlights Key Industry Trends in Pharmaceutical R&amp;D NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) \u2014\u00a0Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and The American Society of Gene &amp; Cell Therapy (ASGCT), today announced the launch of the\u00a0Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report. The [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report - Indonesia Tribune<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report - Indonesia Tribune\" \/>\n<meta property=\"og:description\" content=\"New Report Highlights Key Industry Trends in Pharmaceutical R&amp;D NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) \u2014\u00a0Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and The American Society of Gene &amp; Cell Therapy (ASGCT), today announced the launch of the\u00a0Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report. The [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Indonesia Tribune\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-28T16:05:13+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/indonesiatribune.com\/#\/schema\/person\/7aed831417039bb12c28cffff4aa4192\"},\"headline\":\"Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report\",\"datePublished\":\"2022-04-28T16:05:13+00:00\",\"dateModified\":\"2022-04-28T16:05:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/\"},\"wordCount\":806,\"publisher\":{\"@id\":\"https:\/\/indonesiatribune.com\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/\",\"url\":\"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/\",\"name\":\"Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report - Indonesia Tribune\",\"isPartOf\":{\"@id\":\"https:\/\/indonesiatribune.com\/#website\"},\"datePublished\":\"2022-04-28T16:05:13+00:00\",\"dateModified\":\"2022-04-28T16:05:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/indonesiatribune.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/indonesiatribune.com\/#website\",\"url\":\"https:\/\/indonesiatribune.com\/\",\"name\":\"Indonesia Tribune\",\"description\":\"New Thinking New News\",\"publisher\":{\"@id\":\"https:\/\/indonesiatribune.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/indonesiatribune.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/indonesiatribune.com\/#organization\",\"name\":\"Indonesia Tribune\",\"url\":\"https:\/\/indonesiatribune.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/indonesiatribune.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/indonesiatribune.com\/wp-content\/uploads\/2023\/05\/Indonesia-Tribune-e1700732543917.png\",\"contentUrl\":\"https:\/\/indonesiatribune.com\/wp-content\/uploads\/2023\/05\/Indonesia-Tribune-e1700732543917.png\",\"width\":365,\"height\":87,\"caption\":\"Indonesia Tribune\"},\"image\":{\"@id\":\"https:\/\/indonesiatribune.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/indonesiatribune.com\/#\/schema\/person\/7aed831417039bb12c28cffff4aa4192\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/indonesiatribune.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/indonesiatribune.com\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report - Indonesia Tribune","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/","og_locale":"en_US","og_type":"article","og_title":"Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report - Indonesia Tribune","og_description":"New Report Highlights Key Industry Trends in Pharmaceutical R&amp;D NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) \u2014\u00a0Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and The American Society of Gene &amp; Cell Therapy (ASGCT), today announced the launch of the\u00a0Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report. The [\u2026]","og_url":"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/","og_site_name":"Indonesia Tribune","article_published_time":"2022-04-28T16:05:13+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/#article","isPartOf":{"@id":"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/"},"author":{"name":"admin","@id":"https:\/\/indonesiatribune.com\/#\/schema\/person\/7aed831417039bb12c28cffff4aa4192"},"headline":"Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report","datePublished":"2022-04-28T16:05:13+00:00","dateModified":"2022-04-28T16:05:13+00:00","mainEntityOfPage":{"@id":"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/"},"wordCount":806,"publisher":{"@id":"https:\/\/indonesiatribune.com\/#organization"},"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/","url":"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/","name":"Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report - Indonesia Tribune","isPartOf":{"@id":"https:\/\/indonesiatribune.com\/#website"},"datePublished":"2022-04-28T16:05:13+00:00","dateModified":"2022-04-28T16:05:13+00:00","breadcrumb":{"@id":"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/indonesiatribune.com\/informa-pharma-intelligence-and-the-american-society-of-gene-cell-therapy-asgct-launches-gene-cell-rna-therapy-landscape-q1-2022-quarterly-data-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/indonesiatribune.com\/"},{"@type":"ListItem","position":2,"name":"Informa Pharma Intelligence and The American Society of Gene &amp; Cell Therapy (ASGCT) Launches Gene, Cell &amp; RNA Therapy Landscape Q1 2022 Quarterly Data Report"}]},{"@type":"WebSite","@id":"https:\/\/indonesiatribune.com\/#website","url":"https:\/\/indonesiatribune.com\/","name":"Indonesia Tribune","description":"New Thinking New News","publisher":{"@id":"https:\/\/indonesiatribune.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/indonesiatribune.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/indonesiatribune.com\/#organization","name":"Indonesia Tribune","url":"https:\/\/indonesiatribune.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/indonesiatribune.com\/#\/schema\/logo\/image\/","url":"https:\/\/indonesiatribune.com\/wp-content\/uploads\/2023\/05\/Indonesia-Tribune-e1700732543917.png","contentUrl":"https:\/\/indonesiatribune.com\/wp-content\/uploads\/2023\/05\/Indonesia-Tribune-e1700732543917.png","width":365,"height":87,"caption":"Indonesia Tribune"},"image":{"@id":"https:\/\/indonesiatribune.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/indonesiatribune.com\/#\/schema\/person\/7aed831417039bb12c28cffff4aa4192","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/indonesiatribune.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/indonesiatribune.com\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/posts\/66350"}],"collection":[{"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/comments?post=66350"}],"version-history":[{"count":0,"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/posts\/66350\/revisions"}],"wp:attachment":[{"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/media?parent=66350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/categories?post=66350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/tags?post=66350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}